Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Income towards Parent Company (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Income towards Parent Company for 9 consecutive years, with -$60.8 million as the latest value for Q1 2026.

  • For Q1 2026, Income towards Parent Company changed 0.14% year-over-year to -$60.8 million; the TTM value through Mar 2026 reached -$225.7 million, down 856.59%, while the annual FY2025 figure was -$225.7 million, 2226.02% down from the prior year.
  • Income towards Parent Company hit -$60.8 million in Q1 2026 for Bicycle Therapeutics, down from -$26.8 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $127.8 million in Q4 2024 and bottomed at -$79.0 million in Q2 2025.
  • Average Income towards Parent Company over 5 years is -$33.8 million, with a median of -$39.8 million recorded in 2024.
  • Year-over-year, Income towards Parent Company soared 341.5% in 2024 and then tumbled 129.1% in 2025.
  • Bicycle Therapeutics' Income towards Parent Company stood at -$32.0 million in 2022, then plummeted by 65.19% to -$52.9 million in 2023, then skyrocketed by 341.5% to $127.8 million in 2024, then crashed by 121.01% to -$26.8 million in 2025, then plummeted by 126.54% to -$60.8 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at -$60.8 million, -$26.8 million, and -$59.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.